Cytosorbents (CTSO) Capital Expenditures Growth (3y) (2014 - 2026)
Cytosorbents (CTSO) Capital Expenditures Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 9.52% |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn | 27.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.38% |
| Mar 31, 2026 | -72.16% |
| Dec 31, 2025 | 26.40% |
| Sep 30, 2025 | -85.56% |
| Jun 30, 2025 | 27.59% |
| Mar 31, 2025 | -85.88% |
| Dec 31, 2024 | -27.17% |
| Sep 30, 2024 | 28.56% |
| Jun 30, 2024 | -71.73% |
| Mar 31, 2024 | -52.76% |
| Dec 31, 2023 | 49.20% |
| Dec 31, 2022 | -245.31% |
| Sep 30, 2022 | 254.80% |
| Jun 30, 2022 | -76.16% |
| Mar 31, 2022 | 34.41% |
| Dec 31, 2021 | 174.29% |
| Sep 30, 2021 | -261.10% |
| Jun 30, 2021 | 51.78% |
| Mar 31, 2021 | 20.83% |
| Dec 31, 2020 | -26.66% |